Evidence map›Paper›PMID 32456007›Full record

ReviewToxins2020

Targeting the Early Endosome-to-Golgi Transport of Shiga Toxins as a Therapeutic Strategy.

Danyang Li, Andrey Selyunin, Somshuvra Mukhopadhyay

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Toxins, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Targeting the Inside of Cells with Biologicals: Toxin Routes in a Therapeutic Context.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023
    Review
  5. Review
  6. EnterohemorrhagicInternational journal of molecular sciences · 2022
    Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Danyang LiDivision of Pharmacology & Toxicology, College of Pharmacy, Institute for Cellular & Molecular Biology, and Institute for Neuroscience, The University of Texas at Austin, Austin, TX 78712, USA.
Andrey SelyuninDivision of Pharmacology & Toxicology, College of Pharmacy, Institute for Cellular & Molecular Biology, and Institute for Neuroscience, The University of Texas at Austin, Austin, TX 78712, USA.
Somshuvra MukhopadhyayDivision of Pharmacology & Toxicology, College of Pharmacy, Institute for Cellular & Molecular Biology, and Institute for Neuroscience, The University of Texas at Austin, Austin, TX 78712, USA.
The University of Texas at Austin · US

Funding

Retrograde trafficking of Shiga toxin 2R21AI123608 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI MUKHOPADHYAY, SOMSHUVRA · 2017 to 2018
$430k
National Institute of Allergy and Infectious Diseases R21-AI123608NIAID NIH HHS R21 AI123608
6 · The paper itself

Abstract

Shiga toxin (STx) produced by

Indexed as

AnimalsAnti-Bacterial AgentsDysentery, BacillaryEndosomesEscherichia coli InfectionsGolgi ApparatusHost-Pathogen InteractionsHumansMolecular Targeted TherapyProtein TransportShiga-Toxigenic Escherichia coliShiga ToxinsShigellaAnti-Bacterial AgentsShiga Toxinsautophagyearly endosome-to-Golgi traffickingGolgi phosphoprotein 4 (GPP130)HOPS (homotypic fusion and vacuole protein sorting)late endosomeslysosomesmanganesesmall-molecule inhibitortamoxifen

Identifiers

PMID32456007
PMCPMC7290323
OpenAlexW3026536747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.